EP Patent

EP4260848A1 — Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Assigned to Lotus Pharmaceutical Co Ltd · Expires 2023-10-18 · 3y expired

What this patent protects

The invention provides a pharmaceutical composition comprising Nilotinib or a pharmaceutically acceptable salt thereof, and further comprising an insoluble polymeric diluent and an insoluble non-polymeric diluent.The composition may be produced by a process which is manageable, c…

USPTO Abstract

The invention provides a pharmaceutical composition comprising Nilotinib or a pharmaceutically acceptable salt thereof, and further comprising an insoluble polymeric diluent and an insoluble non-polymeric diluent.The composition may be produced by a process which is manageable, controllable, simple and economical. The composition and a solid dosage form containing the composition is stable and show a good rate and degree of release of the active substance.

Drugs covered by this patent

Patent Metadata

Patent number
EP4260848A1
Jurisdiction
EP
Classification
—
Expires
2023-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Lotus Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.